FDA Grants Breakthrough Therapy Designation to Sanofi’s Tolebrutinib for Non-Relapsing Secondary Progressive Multiple Sclerosis

Submitted by admin on December 16, 2024 - 11:35am

Source:

Pharm Exec

News Tags:

Sanofi

tolebrutinib

non-relapsing secondary progressive MS

FDA

Headline:

FDA Grants Breakthrough Therapy Designation to Sanofi’s Tolebrutinib for Non-Relapsing Secondary Progressive Multiple Sclerosis

snippet:

The FDA has granted Breakthrough Therapy Designation (BTD) to Sanofi’s tolebrutinib for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS).

Search form

You are here

FDA Grants Breakthrough Therapy Designation to Sanofi’s Tolebrutinib for Non-Relapsing Secondary Progressive Multiple Sclerosis

FDA Grants Breakthrough Therapy Designation to Sanofi’s Tolebrutinib for Non-Relapsing Secondary Progressive Multiple Sclerosis